Blacklisting Icahn: How Some Drug Companies Keep Out Activists
This article addresses how pharmaceutical companies take precautions against activist firms when using their shares as currency for an acquisition. These bans have gone largely unnoticed by the activist managers, who say shareholders may be harmed when a company limits who can buy its shares.